ArticleCardiovascular and interventional radiology2026
Intratumoural Contrast Tagging During CT-Hepatic Arteriography-Guided Microwave Ablation of Colorectal Liver Metastases (t-CTHA) to Enhance Tumour Targeting and Margin Assessment.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Procedural Micro-Costing of Single-Room Transcatheter CT Hepatic Angiography for Microwave Liver Ablation.Cardiovascular and interventional radiology · 2026Article
- Intra-procedural CT control versus ultrasound only in ultrasound-guided thermal ablation of colorectal liver metastases: a single-centre cohort study.Surgical endoscopy · 2026Article
- Article
- Adjunctive Techniques for Optimizing Percutaneous CT-Guided Cryoablation of Renal Tumours.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate a technique using intratumoural contrast tagging (t-CTHA), to enhance targeting accuracy and confirm ablation margins during CTHA-guided percutaneous microwave ablation (MWA) of colorectal liver metastases (CRLM).
methodsThis prospective AmCORE-based study (August 2022-May 2025) included participants who underwent CTHA-guided MWA procedures for CRLM. Prior to energy delivery, contrast medium was injected into the common hepatic artery, with CT-imaging start delays (7 and 22 s) adjusted based for optimal tumour conspicuity, to allow the contrast to accumulate within the tumour. Successful tagging was defined by either complete and homogeneous opacification of the tumour or partial contrast capture aiding alignment during image co-registration. Other outcome measures included adverse events (CTCAE v5.0), local tumour progression-free survival (LTPFS), local control (LC), overall survival (OS), and distant progression-free survival (DPFS).
resultsA total of 35 patients underwent 39 t-CTHA-guided MWA procedures for 68 CRLM. Complete tagging was achieved in 79.4% of tumours, partial tagging in 19.1% and inadequate tagging in one tumour (1.5%). The evaluation of post-ablation triple-phase CTHA images, the analysis of co-registered pre- and post-ablation images, and their combined use accurately correlated with complete ablations in all cases. Adverse events were reported in 15.4% of procedures, with two (5.1%) classified as major. None were associated to the catheter or tagging technique. No LTP was reported over a follow-up period of 6 months (range: 2.2-32.4).
conclusionT-CTHA optimizes real-time tumour conspicuity, improves margin assessment by minimizing shrinkage and misregistration issues, and potentially reduces the risk of LTP. LEVEL OF EVIDENCE III: Local non-random sample.
Indexed as
Identifiers
41219587What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.